RGEN is Repligen Corporation (Healthcare) — a non-dividend-paying stock. Trading at $178.71. Market cap: $11.35B. Capital Quality Rank: 94/100 — Market alpha.
Stock snapshot
| Price | $178.71 |
| Market cap | $11.35B |
| Sector | Healthcare |
| Exchange | NMS |
| Pays dividend | No |
Capital Quality & fundamentals
DiviDrip's Capital Analytics engine ranks every non-dividend stock 1-100 on a 4-factor composite (Shareholder Yield 30%, Cash-Flow ROI 25%, Operating Momentum 25%, Tail-Risk 20%) — sector-neutralized so a biotech isn't penalized for negative earnings the way a utility would be.
| Capital Quality Rank (1-100) | 94 / 100 · Market alpha |
| ROIC (TTM) | 2.1% |
| Revenue CAGR (3y) | -2.7% |
| Shareholder buyback yield | -1.10% |
| Altman Z-score zone | Safe |
Valuation, price chart & technicals
Valuation Multiples— the whole story at a glance
vs 1073 Healthcare peers (median)PEG (rev) uses P/E ÷ revenue-growth-% (analyst PEG not published).
PEG (rev) colour: ≤ 1.0 cheap · 1–2 fair · > 2 rich. Lower = the stock's price is rising slower than its growth.
Price Chart
+13.53%Technicals
About RGEN
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Related non-dividend companies
Other non-dividend stocks investors research alongside RGEN. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is RGEN's current stock price?
RGEN (Repligen Corporation) is currently trading at $178.71.
Does RGEN pay a dividend?
RGEN (Repligen Corporation) does not currently pay a regular dividend.
What is RGEN's Capital Quality Rank?
RGEN has a Capital Quality Rank of 94/100 — Market alpha. This score blends ROIC, revenue growth, buybacks, and balance-sheet health.
Track RGEN in DiviDrip
Add RGEN to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search RGEN and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-10-23. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.